Synthesis of Novel Benzenesulfonamide-Bearing Functionalized Imidazole Derivatives as Novel Candidates Targeting Multidrug-Resistant Mycobacterium abscessus Complex.
Benas BalandisPovilas KavaliauskasBirutė GrybaitėVidmantas PetraitisPovilas KavaliauskasEthan NaingAndrew GarciaRamunė GrigalevičiūtėVytautas MickevičiusPublished in: Microorganisms (2023)
Infections caused by drug-resistant (DR) Mycobacterium abscessus ( M. abscessus ) complex (MAC) are an important public health concern, particularly when affecting individuals with various immunodeficiencies or chronic pulmonary diseases. Rapidly growing antimicrobial resistance among MAC urges us to develop novel antimicrobial candidates for future optimization. Therefore, we have designed and synthesized benzenesulfonamide-bearing functionalized imidazole or S- alkylated derivatives and evaluated their antimicrobial activity using multidrug-resistant M. abscessus strains and compared their antimycobacterial activity using M. bovis BCG and M. tuberculosis H37Ra. Benzenesulfonamide-bearing imidazole-2-thiol compound 13, containing 4-CF 3 substituent in benzene ring, showed strong antimicrobial activity against the tested mycobacterial strains and was more active than some antibiotics used as a reference. Furthermore, an imidazole-bearing 4-F substituent and S-methyl group demonstrated good antimicrobial activity against M. abscessus complex strains, as well as M. bovis BCG and M. tuberculosis H37Ra. In summary, these results demonstrated that novel benzenesulfonamide derivatives, bearing substituted imidazoles, could be further explored as potential candidates for the further hit-to-lead optimization of novel antimycobacterial compounds.
Keyphrases
- multidrug resistant
- drug resistant
- mycobacterium tuberculosis
- acinetobacter baumannii
- antimicrobial resistance
- gram negative
- public health
- escherichia coli
- rheumatoid arthritis
- klebsiella pneumoniae
- quantum dots
- pulmonary hypertension
- ankylosing spondylitis
- emergency department
- hiv aids
- staphylococcus aureus
- current status
- cystic fibrosis
- risk assessment
- pseudomonas aeruginosa
- molecular docking
- mass spectrometry
- adverse drug
- disease activity
- systemic sclerosis
- simultaneous determination
- molecular dynamics simulations
- climate change
- hiv infected
- antiretroviral therapy